Should I buy, hold, or sell CLDI stock right now?

Calidi Biotherapeutics Inc. (CLDI) currently earns a Roarable Rating of E (Strong Sell — SELL) with 31/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is CLDI's 12-month price target and RQD AI Jury consensus?

CLDI's 12-month base price target is $0.58 (range $0.45 to $28.39), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Stock Ratings / Health Care / CLDI

PMCB (34) LIMN (35) CRIS (27) BTTC (38) ⌘ Pro Terminal →

Calidi Biotherapeutics Inc. (CLDI) — RQD Stock Rating Cockpit

$0.66 -4.36% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.65

Calidi Biotherapeutics Inc. (CLDI) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $2.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CLDI Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CLDI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Calidi Biotherapeutics Inc. (NYSE: CLDI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $0.66 (-4.36% 1D, market cap $2.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, CLDI ranks #784 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CLDI compare to PMCB and LIMN in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CLDI carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PMCB (PharmaCyte Biotech Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -30.2%, cap $3.2M) and LIMN (Liminatus Pharma Inc. (Class A)) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $3.8M). Among the 5-stock peer group, CLDI leads on earnings multiple (N/A) while PMCB leads on capital efficiency (-30.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CLDI?

▼

Per CLDI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001855485), Calidi Biotherapeutics Inc. generated $56.7M in revenue (-7.1% YoY), -$19.9M in net income, and -$21.3M in free cash flow against $8.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.65 (-0.97%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-12.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CLDI)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (31/100 Composite)

🔍 WHY CLDI SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (32% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (29% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 30.3 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$0.90-14.4% Next Q

Q2 (-2Q)

Grade E$0.77-14.3% Next Q

Q3 (-1Q)

Grade E$0.66+0% Next Q

Current

Grade E$0.66-9.4% Hist 90D α

Trajectory: E (39) → E (31)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CLDI Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CLDI currently carries a cautious 31/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.04) and Max Pain ($0.69) forces dealer call-delta covering toward $28.39.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CLDI• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CLDI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 31%NO 69%Trade / Inspect Odds →

RSI-14 MOMENTUMOVERSOLD (<32)

30.330 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

2 / 99-Pt Accounting

52-WEEK LASER RANGE2% OF RANGE

L: $1$0.66H: $27

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 4 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 8 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 19 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on CLDI

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (20)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (28)

8/40 institutional & smart-money positioning score with 9/20 macro alignment.

Bull Case: Why Buyers Like CLDI

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CLDI)

✓Walkthrough of CLDI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CLDI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -80.53%⚡ TESTING RESISTANCE

2026-11-03O $0.67H $0.69L $0.66C $0.66VOL 48.4K

RES: $0.85SUP: $0.51SMA50: $1.04SMA200: $4.28

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CLDI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CLDI Butterfly Map → + Track CLDI →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. -7.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CLDI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CLDI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CLDI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CLDI)

Health Care Rank #784 of 1015 ⚔️ PMCB vs CLDI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CLDI vs. PMCB, LIMN, CRIS, BTTC)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Calidi Biotherapeutics Inc. (CLDI) ranks #784 by composite RQD confidence (31/100, grade E) and #983 by equity capitalization ($2.5M). Within this direct 5-issuer industry benchmark cohort, CLDI leads on earnings valuation at N/A trailing P/E, while PMCB leads on capital efficiency and profitability with -30.2% ROIC and — gross margin. BTTC currently holds the highest overall quantitative score in the immediate peer group at 38/100 (D-) compared with CLDI at 31/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CLDI ACTIVE Calidi Biotherapeutics Inc.	E	31/100	—	—	-35.0%	-4.36%	$2.5M	Benchmark Subject
PMCB PharmaCyte Biotech Inc.	E	34/100	—	—	-30.2%	+2.71%	$3.2M	/pmcb-vs-cldi →
LIMN Liminatus Pharma Inc. (Class A)	D-	35/100	—	—	-35.0%	-10.64%	$3.8M	/limn-vs-cldi →
CRIS Curis Inc.	E	27/100	—	—	-35.0%	+10.17%	$4.0M	/cris-vs-cldi →
BTTC Black Titan Corporation	D-	38/100	—	—	—	-3.17%	$4.8M	/bttc-vs-cldi →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001855485 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Calidi Biotherapeutics Inc. (CLDI) reported GAAP revenue of $56.7M (-7.1% vs. FY2024 revenue of $61.0M , and -30.2% cumulative change since FY2023) , GAAP net income of -$19.9M, operating cash flow of -$21.3M, and free cash flow of -$21.3M (-8.1% YoY). On the balance sheet, CLDI closed FY2025 with $8.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$56.7M	-$19.9M	-$21.3M	-$21.3M	$8.9M	—
FY2024 (FY)	2024-12-31	$61.0M	-$22.1M	-$19.7M	-$19.7M	$14.2M	—
FY2023 (FY)	2023-12-31	$81.2M	-$29.2M	-$27.0M	-$27.0M	—	—

3. CLDI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CLDI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does CLDI compare to PMCB and LIMN in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for CLDI?

Where is CLDI trading relative to its 50-day, 200-day, and 52-week technical levels?

CLDI last traded at $0.66 (-4.36% on volume of 33,051 shares), positioning the stock -36.54% below its 50-day simple moving average ($1.04) and -84.58% below its 200-day simple moving average ($4.28). Across its 52-week range of $0.62 to $27.04, CLDI sits at the 0.2% percentile with a 14-day RSI of 30.3 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.74).

Direct Sub-Reports: CLDI RQD Cockpit CLDI 12M Forecast CLDI Earnings & Move CLDI Dividends & DRIP CLDI Insiders & 13F CLDI Whale Options CLDI Profit Sankey CLDI News & Why

ROARABLE RATING BRIEF • RQD 31/100 (E) ✓ SEC XBRL & RQD VERIFIED

CLDI — Calidi Biotherapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Calidi Biotherapeutics Inc. (CLDI) earns a live Roarable RQD composite score of 31/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.66 (-4.36% 1D, market capitalization $2.5M).

Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (9/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Calidi Biotherapeutics Inc. Is listed on the NYSE in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry,.. — describes the product, customer base, or revenue model in detail.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Calidi Biotherapeutics Inc. (CLDI) reported $56.7M in annual revenue (up from $61.0M in FY2024, -7.1% YoY) and -$19.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($81.2M revenue, -$29.2M net income) through FY2025, CLDI scaled operating cash flow to -$21.3M and free cash flow to -$21.3M, backed by $8.9M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 31/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.62 – $27.04 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), CLDI carries a macro regime beta of 1.00 and gross margin of —.

Key Question #1: Can CLDI sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $56.7M and free cash flow of -$21.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is CLDI's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CLDI Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Calidi Biotherapeutics Inc. (CLDI) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CLDI Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 22h ago

Stock Splits Calendar for:

Yahoo Finance report covering Calidi Biotherapeutics Inc. (CLDI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GlobeNewswire • 1d ago

Calidi Biotherapeutics to Present New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026

GlobeNewswire report covering Calidi Biotherapeutics Inc. (CLDI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST TradingKey • 1d ago

Top U.S. Stock Gainers: Biggest Price Increases

TradingKey report covering Calidi Biotherapeutics Inc. (CLDI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.dars.gov.et/ • 1d ago

CLDI Q4 2025 Earnings: Narrower-Than-Expected Loss of $6.88 Per Share Against a Pre-Revenue Backdrop

https://www.dars.gov.et/ report covering Calidi Biotherapeutics Inc. (CLDI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 7d ago

Calidi Biotherapeutics Presented New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026, Including Highlighting the Potential of its RedTail Gene Medicine Platform to Turn Tumors into Localized TCE Biofactories

Single-dose CLD-401 induced tumor regression and complete response in 80% of mice in EMT6 breast tumor model Building on the growing clinical evidence supporting T-cell engagers in solid tumors, data showed the platform

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 7d ago

Calidi Biotherapeutics Reports Two Posters At European Society For Medical Oncology From Its RedTail Platform

Calidi Biotherapeutics, Inc. (NYSE American: CLDI) ("Calidi" or "the Company"), a biotechnology company pioneering the development of targeted genetic medicines, announced that it presented two posters

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 15d ago

Calidi Biotherapeutics To Present Preclinical Data On CLD-401 And In Situ T-Cell Engager Programs At ESMO 2026, Highlighting Tumor Eradication And Antitumor Activity Findings

Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or "the Company"), a biotechnology company pioneering the development of targeted genetic medicines, announced that it will be presenting two posters at

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CLDI Bull vs. Bear Conversation Board — What's Your Call at $0.66?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CLDI 🐻 33% BEARISH CONVICTION

MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $0.90 (+30.4%)

📌 Pinned Debate

The Roarable Macro Regime Fit pillar scores 9 / 20 on beta of 1.0, the strongest of its five pillars, and the company has a scheduled E

Don't sleep on CLDI's setup in Health Care. The Roarable Macro Regime Fit pillar scores 9 / 20 on beta of 1.0, the strongest of its five pillars, and the company has a scheduled ESMO 2026 pipeline presentation.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (31/100) backs up the fundamental quality.

EarningsSniper 🐂 BULL

@MultipleCompression Shorting a 3/20 institutional whale-flow stock at $0.69 is dangerous when funds are rotating into Health Care.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $0.52 (-24.6%)

Spot @ $0.69

The company reports zero revenue, operating losses of $20.2M to $29.0M across three years, ROIC of -35%, and a Piotroski F-Score of 2/9

Here is the bear case nobody on the bull side wants to address on CLDI: The company reports zero revenue, operating losses of $20.2M to $29.0M across three years, ROIC of -35%, and a Piotroski F-Score of 2/9 with a 2/20 insider conviction pillar.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Biological Products (No Diagnostic Substances) triggers a 12-15% air pocket.